Menactra May Require More Data For Approval, Advisory Committee Chair Says
This article was originally published in The Pink Sheet Daily
Executive Summary
"There are a number of issues" related to the meningococcal conjugate vaccine, committee chair Overturf tells National Vaccine Advisory Committee. Sanofi-Aventis says it has not submitted any additional data to FDA on Menactra.
You may also be interested in...
Where’s Menactra? No Word From Sanofi-Aventis As User Fee Date Passes
The estimated user fee deadline for the meningococcal conjugate vaccine was Oct. 18. FDA says the vaccine is not currently a licensed product; Sanofi-Aventis has not announced an action by the agency.
Where’s Menactra? No Word From Sanofi-Aventis As User Fee Date Passes
The estimated user fee deadline for the meningococcal conjugate vaccine was Oct. 18. FDA says the vaccine is not currently a licensed product; Sanofi-Aventis has not announced an action by the agency.
Sanofi-Aventis' Menactra Post-Approval Commitments Should Include Long-Term Safety, Efficacy Data
The quadravalent meningococcal conjugate vaccine displayed immunogenicity and safety similar to Menomune, an FDA Advisory Committee says. Sanofi-Aventis says that preliminary results from a three-year follow-up study suggest that Menactra patients have longer antibody persistence than Menomune.